RE: This is Poor research12 May 2021 20:05
Why does every detractor talk about our 2020 revenues as if they're anything to with the fair value of Avacta? The potential sales from our LFT, Affimer licensing, AVA6000, Pre|Cision, TMAC etc, all add massive value to Avacta above the likes of Nova, who are a purely Covid revenue generating company.
I hate the, "us versus them" mentality, but these companies are completely different and should not be compared in such a rudimentary manner.